Hemophilia A clinical trials

Explore recruiting hemophilia a clinical trials.

Recruiting hemophilia a studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hemophilia A trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients with Mild or Moderate Hemophilia A without FVIII Inhibitors

Germany, France, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

A study to test a medicine (fitusiran) for preventing bleeds in people with severe hemophilia who previously received preventive treatment with emicizumab

Italy, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons with Severe or Moderate Hemophilia A

Italy, Poland, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

C3731003 Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C≤1%)

Germany, Spain, France, Greece, Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

Pharmacokinetic-guided dosing of emicizumab in congenital haemophilia A patients – The DosEmi study

Netherlands

Phase III and phase IV (Integrated) EU CTIS Study details

(19429) A phase 1/2 open-label safety and dose-finding study of BAY 2599023 (DTX201), an adeno-associated virus (AAV) hu37-mediated gene transfer of B-domain deleted human factor VIII, in adults with severe hemophilia A

Netherlands, Germany, France, Bulgaria

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Hemophilia A trials by city

Hemophilia A in Toronto Hemophilia A in Vancouver Hemophilia A in Montreal Hemophilia A in Calgary Hemophilia A in Edmonton Hemophilia A in Ottawa Hemophilia A in Winnipeg Hemophilia A in Quebec City Hemophilia A in Hamilton Hemophilia A in Kitchener Hemophilia A in London Hemophilia A in Halifax Hemophilia A in New York Hemophilia A in Los Angeles Hemophilia A in Chicago Hemophilia A in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease